Clinical Trials Browser

Phase 2 × Liver Neoplasms × Tyrosine Kinase Inhibitors × Clear all

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Phase 2 Unknown

Gastrointestinal

Liver Neoplasms